Gauze G F, Brazhnikova M G, Lomakina N N, Gol'dberg L E, Laĭko A V
Antibiot Khimioter. 1989 May;34(5):348-52.
Eremomycin is a novel antibacterial antibiotic. It was isolated at the Institute of New Antibiotics, the USSR Academy of Medical Sciences from the culture fluid of actinomycete INA-238. By its physico-chemical and biological properties the antibiotic was classified as belonging to the group of polycyclic glycopeptides. Chemical structure of eremomycin was asserted and it was shown to be a new representative of the group close by its structure to vancomycin and differing from it by the carbohydrate composition and structure of tri-phenoxytriaminotricarboxylic acid. By its anti-bacterial spectrum eremomycin was found to be close to ristomycin and vancomycin. Still, its activity was 2-10 times higher. The antibiotic was several times less toxic than vancomycin. Unlike vancomycin and ristomycin, the novel antibiotic induced no tissue necrosis after its intramuscular administration. The chemotherapeutic indices of eremomycin in treatment of staphylococcal and streptococcal sepsis in albino mice exceeded 10 times those of vancomycin. At present eremomycin is under clinical trials.
埃瑞霉素是一种新型抗菌抗生素。它是由苏联医学科学院新抗生素研究所从放线菌INA - 238的培养液中分离出来的。根据其物理化学和生物学特性，该抗生素被归类为多环糖肽类。埃瑞霉素的化学结构已得到确定，结果表明它是该类别的一个新代表，其结构与万古霉素相近，但在碳水化合物组成和三苯氧基三氨基三羧酸的结构上与万古霉素不同。就抗菌谱而言，埃瑞霉素与瑞斯托霉素和万古霉素相近。不过，其活性要高2至10倍。该抗生素的毒性比万古霉素低几倍。与万古霉素和瑞斯托霉素不同，这种新型抗生素肌肉注射后不会引起组织坏死。埃瑞霉素对白化病小鼠葡萄球菌和链球菌败血症的化疗指数超过万古霉素10倍以上。目前埃瑞霉素正在进行临床试验。
